Avodart Cost in Iowa 2026: Dutasteride Pricing, Insurance, and Savings

What Is the Cash Price of Avodart in Iowa in 2026?

Generic dutasteride 0.5 mg costs roughly $25 per month at Iowa retail pharmacies when patients use a free prescription discount card. Branded Avodart from GSK carries a manufacturer list price of approximately $290 per month, but almost no patient pays that figure out of pocket in 2026. The difference comes down to generic substitution and coupon stacking.

Dutasteride received FDA approval for BPH in November 2001 under the brand name Avodart. The FDA labeling is available on the FDA Access Data portal. Multiple generic manufacturers entered the market after patent expiration, driving retail cash prices down substantially. A 30-capsule supply of generic dutasteride 0.5 mg is listed at $20 to $30 at most Iowa Walgreens, Hy-Vee Pharmacy, and CVS locations when a GoodRx or RxSaver coupon is applied at the counter. Without any coupon, the same supply may ring up at $80 to $120, depending on the pharmacy's usual-and-customary pricing.

Dutasteride is a dual 5-alpha reductase inhibitor (5-ARI) that blocks both type 1 and type 2 isoenzymes, reducing serum dihydrotestosterone (DHT) by approximately 90% at the standard 0.5 mg dose. Traish et al. confirmed that dual 5-ARI blockade suppresses DHT more completely than type-2-only inhibitors such as finasteride. That pharmacologic profile is why prescribers use dutasteride both for FDA-approved BPH management and off-label for androgenetic alopecia (AGA).

Price varies slightly by Iowa city. Des Moines, Cedar Rapids, and Iowa City have high pharmacy density, which tends to keep coupon prices competitive. Smaller towns in western Iowa may have only one or two pharmacies, so it is worth checking prices via GoodRx before heading to the counter. Prices quoted here reflect January 2025 survey data and may shift by a few dollars through 2026.

A 2022 JAMA Internal Medicine analysis found that prescription discount cards reduced out-of-pocket drug costs by a median of 57% compared to insurance copays for commonly prescribed generics. Dutasteride sits squarely in that generic category.

Does Iowa Medicaid Cover Dutasteride?

Iowa Medicaid does not include dutasteride on its standard preferred drug list (PDL) for either BPH or androgenetic alopecia as of the 2025 formulary cycle. Patients enrolled in Iowa Medicaid (Iowa Health and Wellness Plan or hawk-i for children) will find no automatic coverage for this drug.

Iowa Medicaid is administered through managed care organizations (MCOs) including UnitedHealthcare Community Plan and Molina Healthcare of Iowa. Each MCO maintains its own formulary, but all three currently omit dutasteride without a prior authorization pathway for BPH. Finasteride 5 mg (generic Proscar) is sometimes listed as the preferred 5-ARI for BPH on Iowa Medicaid PDLs because its cash cost is even lower than dutasteride. The 2010 COMBAT trial (N=1,610) demonstrated that the dutasteride plus tamsulosin combination reduced BPH symptom progression more than either drug alone over 4 years, but clinical superiority does not automatically translate into Medicaid formulary inclusion when a cheaper alternative exists.

For hair loss specifically, Iowa Medicaid follows federal guidance treating AGA as a cosmetic condition. No 5-ARI is covered for this indication under any Iowa Medicaid MCO plan.

Patients in the Iowa Medicaid Medically Needy program or those with a documented medical exception may submit a prior authorization (PA) request. PA approval rates for dutasteride in Iowa are not publicly published, but in neighboring states with similar PDL structures, PA approval for BPH when finasteride has failed runs at approximately 30 to 50 percent. Documenting a finasteride trial of at least 6 months, with documented inadequate response or intolerability, strengthens a PA application substantially.

The Endocrine Society's 2010 guideline on male hypogonadism and related androgen-sensitive conditions notes that 5-alpha reductase inhibitors are first-line agents for BPH but requires individualized risk-benefit assessment.

Which Private Insurance Plans Cover Avodart in Iowa?

Most Iowa commercial plans cover generic dutasteride at Tier 2 or Tier 3, with typical copays of $10 to $45 per month after the deductible. Branded Avodart, where it remains on formulary at all, usually sits at Tier 4 or 5 with copays of $60 to $120 per month. Switching to generic at the pharmacy counter eliminates that cost gap in most cases.

Iowa's largest commercial payers in 2026 include Wellmark Blue Cross Blue Shield of Iowa, UnitedHealthcare (employer and exchange plans), Medica, and Sanford Health Plan. Wellmark BCBS of Iowa places generic dutasteride 0.5 mg on its Tier 2 formulary for BPH across most plan designs, with a standard 30-day copay of $15 to $30. UnitedHealthcare employer plans in Iowa vary widely by the employer's benefit design, but the majority of mid-to-large employer plans tier generic dutasteride at Tier 2.

Medicare Part D in Iowa is another common coverage vehicle for older men treated for BPH. The Centers for Medicare and Medicaid Services (CMS) 2025 Part D formulary data show that roughly 65% of stand-alone PDP plans available in Iowa cover generic dutasteride, most at Tier 2. During the 2025 plan year, the standard initial coverage copay for Tier 2 drugs under Iowa Part D plans ranged from $0 to $15 per 30-day fill. The Medicare Prescription Payment Plan (M3P) available beginning in 2025 allows patients to spread out-of-pocket costs over the calendar year, which can help patients who enter the coverage gap.

For off-label hair-loss use, most commercial plans in Iowa explicitly exclude the indication, meaning the drug is billed under a cosmetic exclusion clause regardless of plan tier. Patients paying for dutasteride for AGA almost always do so out of pocket.

A 2021 JAMA Dermatology study (N=3,114) confirmed that dutasteride 0.5 mg once daily produced significantly greater improvements in hair density scores at 24 weeks compared to finasteride 1 mg (P<0.001) in men with AGA.

Is Compounded Dutasteride Legal in Iowa?

Yes. Iowa-licensed 503A compounding pharmacies may legally prepare dutasteride formulations for individual patients when a prescriber writes a valid patient-specific prescription. This is distinct from 503B outsourcing facilities, which manufacture in bulk and are regulated more stringently by the FDA.

Iowa Code Chapter 155A governs pharmacy practice, and the Iowa Board of Pharmacy permits 503A compounding of commercially available drug substances including dutasteride, provided the compounded preparation is not a copy of a commercially available product and is prepared pursuant to a valid prescription. In practice, compounded dutasteride in Iowa is typically prepared as an oral capsule or topical solution at doses or concentrations not commercially available, such as 0.1 mg, 0.25 mg, or combined formulations with minoxidil or other actives for hair restoration.

Compounded dutasteride from an Iowa 503A pharmacy costs approximately $40 per month, which is higher than the $25 cash price for generic oral capsules but potentially useful when a non-standard dose or delivery form is clinically indicated. The FDA's guidance on compounding from bulk drug substances outlines when 503A pharmacies may compound drugs that are commercially available.

One legal caveat: Iowa pharmacies may not compound a preparation that is essentially a copy of a commercially available product. If a prescriber orders dutasteride 0.5 mg oral capsules from a 503A pharmacy, that is functionally identical to the branded or generic product and could be considered an impermissible copy. Prescribers ordering compounded dutasteride should specify a non-standard dose or formulation with clinical rationale documented in the chart.

Gupta and Charrette (2014) reviewed topical finasteride and dutasteride as emerging delivery methods in AGA, supporting the clinical rationale for non-standard formulations.

HealthRX Iowa Compounded Dutasteride Decision Framework

Use this four-question checklist before routing an Iowa patient to a 503A pharmacy for compounded dutasteride:

1. Is a non-standard dose or formulation (not 0.5 mg oral capsule) clinically indicated? If no, dispense generic from retail.
2. Has the prescriber documented clinical rationale for the compounded form in the chart? If no, document first.
3. Is the compounding pharmacy licensed by the Iowa Board of Pharmacy and registered with the FDA? Verify before writing the script.
4. Does the patient understand that compounded products are not FDA-reviewed for efficacy and safety in the same manner as approved generics? Obtain verbal or written consent.

Can Iowa Patients Get Dutasteride Via Telehealth?

Iowa telehealth law, updated under Iowa Code Section 135.185 (effective 2022), permits prescribers licensed in Iowa to conduct a valid patient-physician relationship via synchronous audio-video technology and prescribe non-controlled medications including dutasteride. No in-person visit is required to initiate a dutasteride prescription in Iowa as long as the prescriber obtains a complete history, reviews relevant labs or imaging if indicated, and documents the clinical encounter appropriately.

Dutasteride is not a controlled substance under federal or Iowa law, so Ryan Haight Act restrictions that apply to schedule II through IV medications do not apply here. A telehealth prescriber in Iowa may transmit a dutasteride prescription electronically to any Iowa-licensed pharmacy. The Federation of State Medical Boards' telemedicine policy guidelines support electronic prescribing of non-controlled substances following a synchronous audio-video evaluation.

HealthRX clinicians conduct a structured intake that includes a full symptom history, AUA Symptom Score (for BPH patients), a review of any prior 5-ARI trials, and documentation of relevant comorbidities such as prostate cancer screening history. Men over 50 starting a 5-ARI for BPH should have a documented baseline PSA, because dutasteride lowers PSA by approximately 50% within 6 months. The FDA label for dutasteride specifically states that PSA values should be doubled for comparison to normal ranges in men not taking 5-ARIs. Failing to account for this adjustment can mask a rising PSA that signals early prostate cancer.

Telehealth prescribing also works well for AGA. The evidence base for dutasteride in AGA has grown since Eun et al. published a randomized controlled trial in the Journal of the American Academy of Dermatology (2010, N=153) showing that dutasteride 0.5 mg daily produced significantly greater increases in total hair count at 24 weeks compared to finasteride 1 mg (P<0.001). That trial is indexed at PubMed (PMID 20691790). These results support off-label use, which a telehealth clinician can prescribe in Iowa with appropriate informed consent documentation.

What Are the Cheapest Ways to Get Dutasteride in Iowa?

The single lowest out-of-pocket cost path in Iowa is generic dutasteride 0.5 mg with a free GoodRx Gold or RxSaver coupon at a high-volume pharmacy. Hy-Vee Pharmacy locations in Des Moines, Cedar Rapids, Davenport, and Sioux City consistently show prices of $18 to $28 per 30-capsule fill on these platforms. Walmart Pharmacy in Iowa currently offers a 30-day supply of generic dutasteride through its $4/$10 generic program at select locations, making it one of the least expensive options available anywhere in the state.

A 2019 JAMA analysis of Walmart's generic drug program found that it reduced patient costs for included generics by a mean of 79% compared to national average retail prices. Dutasteride has been included in the Walmart program at Iowa stores since 2023.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists dutasteride 0.5 mg at approximately $14 for 30 capsules with free home delivery to Iowa addresses. That price is transparent: it reflects the acquisition cost plus a fixed 15% markup plus a $3 pharmacist fee. No coupon or insurance card is needed.

For patients already enrolled in a commercial plan that covers dutasteride, using insurance at Tier 2 with a $10 to $15 copay is comparable to the cash-pay coupon route. Patients should not automatically assume insurance is cheaper. Checking the GoodRx or Cost Plus price before handing over the insurance card at the counter takes 30 seconds and can occasionally reveal a lower cash price.

The 2022 JAMA Internal Medicine study on discount card vs. insurance pricing (N=1.9 million prescriptions) found that the discount card price was lower than the insurance copay for 25% of common generic prescriptions.

Mark down: three-month (90-day) supplies typically cost less per unit than 30-day fills. A 90-day supply of generic dutasteride via Cost Plus Drugs is approximately $30, which works out to $10 per month.

Savings Cards and Manufacturer Programs for Dutasteride in Iowa

GSK no longer markets branded Avodart as a commercial priority in the US generic market. The GSK patient assistance program (PAP), historically available through GSK for Patients, covered Avodart for uninsured or underinsured patients with incomes below 400% of the federal poverty level. As of 2025, the GSK for Patients program has wound down active enrollment for Avodart given generic availability. Patients seeking manufacturer support should contact GSK directly at 888-825-5249 to confirm current program status.

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain searchable databases of patient assistance programs for dutasteride generics. Several generic manufacturers including Mylan (now Viatris) and Amneal Pharmaceuticals have offered co-pay assistance cards for their dutasteride products. Eligibility typically requires commercial (non-government) insurance and a valid US prescription. Iowa patients on Medicare or Medicaid are not eligible for manufacturer co-pay cards under federal Anti-Kickback Statute rules.

The Department of Health and Human Services Office of Inspector General has published guidance clarifying that manufacturer co-pay cards for government-insured patients violate the Anti-Kickback Statute.

Iowa also has a State Pharmaceutical Assistance Program (SPAP) for Medicare beneficiaries called the Iowa Senior Living Trust Fund, although its formulary and income thresholds shift annually. As of 2024, dutasteride was not included in the SPAP formulary.

The most reliable savings strategy for most uninsured or underinsured Iowa patients remains the combination of generic substitution plus a free discount card, with Cost Plus Drugs as a backup for maximum price transparency. No Iowa-specific drug rebate program currently targets dutasteride by name.

Side Effects and Monitoring Considerations for Iowa Prescribers

Dutasteride is generally well tolerated. The most commonly reported adverse effects in clinical trials are sexual in nature, including decreased libido (reported by 3 to 5% of patients in the COMBAT trial at 4 years), erectile dysfunction (approximately 5%), and ejaculation disorders (approximately 1%). The 4-year COMBAT trial (N=1,610) published in BJU International demonstrated that combination dutasteride/tamsulosin therapy reduced the relative risk of acute urinary retention by 68% compared to placebo.

The FDA added a label warning in 2011 noting a possible increased risk of high-grade prostate cancer (Gleason score 8 to 10) in men taking 5-ARIs in the REDUCE trial. The REDUCE trial (N=6,729) found that dutasteride reduced prostate cancer incidence by 22.8% overall, but a small numerical increase in Gleason 8 to 10 cancers was observed in the dutasteride arm (1.0% vs. 0.5%, absolute difference 0.5%). The FDA label update reflects this finding. Iowa prescribers should discuss this risk explicitly with patients, particularly those with a family history of prostate cancer.

Dutasteride has a very long half-life of approximately 5 weeks, meaning serum levels accumulate for months and the drug persists in the body for up to 6 months after the last dose. This is relevant for Iowa patients who plan to donate blood (current FDA guidance recommends a 6-month deferral period after the last dose) and for women of childbearing potential, who must not handle crushed or opened dutasteride capsules because of teratogenic risk. The FDA's drug safety communication on 5-ARI risks is available at the FDA website.

Iowa prescribers should obtain a baseline PSA before starting dutasteride in men over 40 with BPH, recheck PSA at 6 months to establish the new baseline (expected to be approximately 50% of pretreatment value), and continue annual PSA monitoring thereafter. Any PSA rise above the new baseline should trigger urology evaluation.